UA66847C2 - Тверда швидкорозчинна композиція селегіліну та спосіб її одержання - Google Patents

Тверда швидкорозчинна композиція селегіліну та спосіб її одержання

Info

Publication number
UA66847C2
UA66847C2 UA2000106081A UA00106081A UA66847C2 UA 66847 C2 UA66847 C2 UA 66847C2 UA 2000106081 A UA2000106081 A UA 2000106081A UA 00106081 A UA00106081 A UA 00106081A UA 66847 C2 UA66847 C2 UA 66847C2
Authority
UA
Ukraine
Prior art keywords
fizzy
selegiline
production
dosage form
rapidly decomposing
Prior art date
Application number
UA2000106081A
Other languages
English (en)
Russian (ru)
Inventor
Вольфрам Тріттхарт
Маріо Андре Піскерніг
Готфрід Кьольбль
Original Assignee
Віатріс Гмбх & Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Віатріс Гмбх & Ко. Кг filed Critical Віатріс Гмбх & Ко. Кг
Publication of UA66847C2 publication Critical patent/UA66847C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Винахід стосується твердої швидкорозчинної шипучої композиції селегіліну для перорального застосування, шипуча основа якої складається з одного або кількох карбонатів лужноземельних металів, органічної придатної для внутрішнього споживання кислоти та фармацевтично прийнятних допоміжних речовин, та способу одержання такої композиції.
UA2000106081A 1998-03-31 1999-03-20 Тверда швидкорозчинна композиція селегіліну та спосіб її одержання UA66847C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19814257A DE19814257A1 (de) 1998-03-31 1998-03-31 Brauseformulierungen
PCT/DE1999/000798 WO1999049842A1 (de) 1998-03-31 1999-03-20 Brauseformulierungen

Publications (1)

Publication Number Publication Date
UA66847C2 true UA66847C2 (uk) 2004-06-15

Family

ID=7863015

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2000106081A UA66847C2 (uk) 1998-03-31 1999-03-20 Тверда швидкорозчинна композиція селегіліну та спосіб її одержання

Country Status (29)

Country Link
US (1) US6242002B1 (uk)
EP (1) EP1067905B1 (uk)
JP (1) JP4469494B2 (uk)
KR (1) KR100607395B1 (uk)
CN (1) CN1138529C (uk)
AR (1) AR018829A1 (uk)
AT (1) ATE224703T1 (uk)
AU (1) AU753194B2 (uk)
BG (1) BG65043B1 (uk)
BR (1) BR9909266A (uk)
CA (1) CA2326502C (uk)
CZ (1) CZ300705B6 (uk)
DE (2) DE19814257A1 (uk)
DK (1) DK1067905T3 (uk)
ES (1) ES2183555T3 (uk)
HK (1) HK1036010A1 (uk)
HU (1) HU229793B1 (uk)
IL (1) IL138605A (uk)
NO (1) NO329143B1 (uk)
NZ (1) NZ506989A (uk)
PL (1) PL192049B1 (uk)
PT (1) PT1067905E (uk)
RU (1) RU2221554C2 (uk)
SK (1) SK284477B6 (uk)
TR (1) TR200002812T2 (uk)
TW (1) TW580398B (uk)
UA (1) UA66847C2 (uk)
WO (1) WO1999049842A1 (uk)
ZA (1) ZA200005133B (uk)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US6200604B1 (en) * 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US20030091629A1 (en) 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
AU2004242477B2 (en) * 1999-03-26 2007-04-19 Cima Labs Inc. Sublingual buccal effervescent
AU2007203233B2 (en) * 1999-03-26 2010-02-25 Cima Labs Inc. Sublingual buccal effervescent
KR20030011797A (ko) * 2000-03-28 2003-02-11 바이오케미 게젤샤프트 엠베하 맛이 차폐된 과립형 입자
JP4706096B2 (ja) * 2000-10-23 2011-06-22 大正製薬株式会社 不快な味を呈する塩基性薬物配合製剤
US20030068356A1 (en) * 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
US20040175456A1 (en) * 2003-03-06 2004-09-09 Lauren Keilbach Tablets for feeding fish and methods of making tablets for feeding fish
US20040191298A1 (en) * 2003-03-26 2004-09-30 Fredrik Nicklasson New formulations and use thereof
TR200300510A2 (tr) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
WO2005065319A2 (en) 2003-12-31 2005-07-21 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
AU2004311879B2 (en) * 2003-12-31 2010-08-05 Cima Labs Inc. Effervescent oral opiate dosage form
US7858121B2 (en) 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
US7033511B2 (en) 2004-01-20 2006-04-25 A-Dec, Inc. Sustained water treatment in dental equipment
JP2008500288A (ja) * 2004-05-28 2008-01-10 イメイジノット ピーティーワイ エルティーディー 経口治療用化合物の供給系
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
CN102716490A (zh) * 2005-09-01 2012-10-10 卫材R&D管理有限公司 药物组合物的崩解性的改善方法
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
AU2006317530B2 (en) * 2005-11-28 2011-09-01 Imaginot Pty Ltd Oral therapeutic compound delivery system
PT2361081T (pt) * 2008-10-14 2016-09-05 Mcneil Ab Forma de dosagem intra-oral multiporção e seu uso
KR101233352B1 (ko) * 2009-04-22 2013-02-25 (주)비씨월드제약 유전자 재조합 과립구-대식세포 집락 촉진인자를 함유하는 정제
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
WO2013116112A1 (en) 2012-02-01 2013-08-08 Kraft Foods Global Brands Llc Low calorie drink tablet
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
JP6411379B2 (ja) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN109303334B (zh) * 2018-10-17 2021-04-13 汤臣倍健股份有限公司 一种口腔微泡腾片及其制备方法
ES2945809T3 (es) * 2019-10-02 2023-07-07 Intas Pharmaceuticals Ltd Composiciones farmacéuticas sólidas efervescentes prácticamente sin sodio
US20230242846A1 (en) * 2020-05-28 2023-08-03 Conopco, Inc., D/B/A Unilever Tablet

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678661A (en) * 1983-09-28 1987-07-07 Gerhard Gergely Effervescent composition and method of making same
DE3440288C2 (de) * 1984-11-05 1987-03-12 Gergely, Gerhard, Dr.-Ing., Wien Pharmazeutische Zubereitung mit einem Gehalt an Ibuprofen sowie Verfahren zu ihrer Herstellung
US4861800A (en) 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
GB8807504D0 (en) 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
GB8909793D0 (en) * 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
US5128145A (en) 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
HU209605B (en) 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
DE59202126D1 (de) 1991-07-01 1995-06-14 Gergely Gerhard Verfahren zur Herstellung einer pharmazeutischen Zubereitung mit wenigstens zwei verschiedenen Wirkstoffen und Verwendung einer solchen Zubereitung.
US5415870A (en) * 1991-07-01 1995-05-16 Gerhard Gergely Effervescent systems using reaction doping agents
EP0593807A1 (en) 1992-10-22 1994-04-27 LTS Lohmann Therapie-Systeme GmbH & Co. KG Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
MX9300110A (es) * 1992-01-13 1994-07-29 Gerhard Gergely Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
AU672617B2 (en) * 1992-06-22 1996-10-10 Regents Of The University Of California, The Glycine receptor antagonists and the use thereof
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
FR2698788B1 (fr) * 1992-12-09 1995-03-03 Union Pharma Scient Appl Composition pharmaceutique effervescente contenant de l'ibuprofène et son procédé de préparation.
WO1994017792A2 (en) 1993-01-27 1994-08-18 Affymax Technologies N.V. Compositions and methods for transdermal drug delivery
US5287394A (en) 1993-03-22 1994-02-15 Advanced Micro Devices, Inc. Fast counter with uniform delay structures
SE9301112D0 (sv) 1993-04-02 1993-04-02 Orion-Yhtymae Oy A new composition
ATE140621T1 (de) * 1993-04-15 1996-08-15 Gergely Gerhard Brausesystem mit einem alkali- und/oder metallempfindlichen, pharmazeutischen wirkstoff, und verfahren zur herstellung
AU678237B2 (en) 1993-04-20 1997-05-22 Hexal Pharma Gmbh Active substance-containing plaster
US5503844A (en) 1993-05-18 1996-04-02 Mli Acquisition Corp. Ii Foam laminate transdermal patch
DE59407351D1 (de) 1993-09-09 1999-01-07 Gerhard Gergely Brausegranulat und verfahren zu seiner herstellung
CA2176212C (en) 1993-11-12 2004-09-21 Gerhard Gergely Process for producing a granulated material
US5484608A (en) 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
GB2290965A (en) 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
US5603955A (en) 1994-07-18 1997-02-18 University Of Cincinnati Enhanced loading of solutes into polymer gels
HU223475B1 (hu) 1994-10-24 2004-07-28 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Selegilint tartalmazó liposzoma-készítmény és eljárás ennek előállítására
DE29500718U1 (de) * 1995-01-18 1995-04-06 Rau, Reinhard, 37242 Bad Sooden-Allendorf Element einer Zeltplane zum Aufbau von kohten- und jurtenähnlichen Zeltaufbauten
WO1997017067A1 (en) 1995-11-06 1997-05-15 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline

Also Published As

Publication number Publication date
WO1999049842A1 (de) 1999-10-07
TR200002812T2 (tr) 2001-01-22
IL138605A0 (en) 2001-10-31
BR9909266A (pt) 2000-11-21
NZ506989A (en) 2002-09-27
DE59902843D1 (de) 2002-10-31
CN1295463A (zh) 2001-05-16
IL138605A (en) 2005-11-20
DE19814257A1 (de) 1999-10-07
PT1067905E (pt) 2003-02-28
HUP0101427A2 (hu) 2001-08-28
CA2326502C (en) 2008-08-05
HUP0101427A3 (en) 2001-12-28
KR20010042317A (ko) 2001-05-25
DK1067905T3 (da) 2003-02-03
PL343260A1 (en) 2001-07-30
EP1067905B1 (de) 2002-09-25
RU2221554C2 (ru) 2004-01-20
CA2326502A1 (en) 1999-10-07
AU753194B2 (en) 2002-10-10
AR018829A1 (es) 2001-12-12
NO20004721D0 (no) 2000-09-21
KR100607395B1 (ko) 2006-08-02
CN1138529C (zh) 2004-02-18
ZA200005133B (en) 2001-02-28
TW580398B (en) 2004-03-21
SK14322000A3 (sk) 2001-07-10
JP4469494B2 (ja) 2010-05-26
EP1067905A1 (de) 2001-01-17
CZ20003482A3 (en) 2001-05-16
SK284477B6 (sk) 2005-04-01
BG65043B1 (bg) 2007-01-31
ATE224703T1 (de) 2002-10-15
CZ300705B6 (cs) 2009-07-22
HK1036010A1 (en) 2001-12-21
NO20004721L (no) 2000-09-21
NO329143B1 (no) 2010-08-30
HU229793B1 (en) 2014-07-28
ES2183555T3 (es) 2003-03-16
US6242002B1 (en) 2001-06-05
PL192049B1 (pl) 2006-08-31
JP2002509872A (ja) 2002-04-02
AU4029499A (en) 1999-10-18
BG104841A (en) 2001-07-31

Similar Documents

Publication Publication Date Title
UA66847C2 (uk) Тверда швидкорозчинна композиція селегіліну та спосіб її одержання
AR018828A1 (es) Formulaciones efervescentes solidas de rapida desintegracion para administracion oral.
HK1080364B (zh) 具有改進的生物利用率的液體藥物口服藥物劑型
MY106412A (en) Pharmaceutical compositions.
ES2099275T3 (es) Comprimido multiparticulas de desleimiento rapido.
DK1003486T3 (da) Farmaceutisk præparat indeholdende et bruse-syre-basepar
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
AU2002231654A1 (en) Pharmaceutical paste comprising an acid-labile active ingredient
WO2004100817A3 (en) Oral care tablet
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina
WO2002015933A3 (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
IL150528A0 (en) Ibuprofen containing active agent preparation
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
BG103739A (en) Aqueous pharmaceutical composition containing hard soluble active substance in water
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
HRP20020165B1 (en) Low-dose tablets and preparation method
ATE238034T1 (de) Geschmacksmaskierung schlecht schmeckender formulierungen
MX9707695A (es) Empaque que contiene una formulacion de solucion acuosa de clorhidrato de procaterol, y una formulacion de solucion acuosa de clorhidrato de procaterol.
EP1353624A4 (en) PHARMACEUTICAL COMPOSITIONS OF A NON-GRASS-RESISTANT PROTON PUMP INHIBITOR WITH A CARBONATE AND BICARBONATE SALT COMBINATION
PL350413A1 (en) Pharmaceutical effervescent formulation containing metamizol
GB0006897D0 (en) Medicaments
ECSP972162A (es) Formas solidas de dosificacion oral que contienen valsartan
ES8802560A1 (es) Un metodo para la preparacion de derivados estables efervescentes de acido acetilsalicilico con propiedades antihistaminicas.
ZA200100289B (en) Use of tiludronic acid and derivatives thereof in poultry for the preparation of a medicinal product for preventing and treating osteoporosis.
MY128958A (en) New oral formulation for 5-ht4 agonists or antagonists.